The MS-SMART trial will look at drugs that may limit the progression of MS. Researchers have been recruiting people with secondary progressive MS from across the UK, but are still in need of more people to volunteer to take part.
Ozanimod is a drug that works in a similar way to Gilenya (fingolimod) but with fewer side effects according to recently published research.
Ocrelizumab has become the first new medicine for MS to be granted a special status that could speed up approval by the American drug regulators
News item on campaign to legalise medicinal cannabis.